Prothena reports $621M cash at year-end 2023; pipeline updates on PRX012, PRX123, birtamimab

PROTHENA CORP PUBLIC LTD CO

Cash, cash equivalents, and restricted cash ~$621M as of Dec 31, 2023; sufficient capital beyond ongoing trials.
PRX012 (Alzheimer's): Phase 1 data supports once-monthly dosing; dose escalation to 200-400mg underway.
PRX123 (Alzheimer's vaccine): IND cleared and Fast Track designation; Phase 1 timeline update expected in 2024.
Birtamimab (AL amyloidosis): Phase 3 AFFIRM-AL enrollment on track; topline results expected 4Q24-2Q25.
Partnered programs with BMS, Roche, Novo Nordisk remain on track; BMS-986446 moving to Phase 2 in 1H24.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.